Portola Pharmaceuticals

Patent cliffs & loss of exclusivity

A company developing therapeutics for the treatment of acute and chronic cardiovascular and autoimmune and inflammatory diseases

Company

AngelList URLhttps://angel.co/portola-pharmaceuticals
Legal NamePortola Pharmaceuticals, Inc.
Company Operating StatusClosed
Crunchbase URLhttps://www.crunchbase.com/organization/portola-pharmaceuticals
Full Address270 East Grand Ave., South San Francisco, CA 94080, US
LinkedIn URLhttps://www.linkedin.com/company/portola-pharmaceuticals/
Public/PrivatePublic
Seedtable URLhttps://seedtable.com/companies/portola-pharmaceuticals

2 upcoming patent cliffs

DrugIngredientTypeCliff
  1. BEVYXXABETRIXABANSmall mol.Mar 2031
  2. BEVYXXABETRIXABANSmall mol.Mar 2031

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Portola Pharmaceuticals — patent cliffs & loss of exclusivity | CliffBio